Anacor Pharmaceuticals, Inc. (ANAC) Posts Q3 Loss of $0.16, Sales Fall Y/Y
Tweet
Share
E-mailGet Alerts ANAC Hot Sheet
Join SI Premium – FREE
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) reported Q3 EPS of ($0.16), which may not compare to than the analyst estimate of ($0.41). Revenue for the quarter came in at $12.6 million, versus $16.9 million reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
- Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
- Baidu (BIDU) Misses Q2 EPS by 262c, misses on revenue
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
